FOXM1 expression predicts the prognosis in hepatocellular carcinoma patients after orthotopic liver transplantation combined with the Milan criteria

Cancer Letters

Volumn 306, Issue 2, 2011, Pages 214-222

  Sun, Hongcheng ^a   Teng, Mujian ^b   Liu, Jie ^b   Jin, Dong ^c   Wu, Junyi ^a   Yan, Dongwang ^a   Fan, Junwei ^a   Qin, Xuebin ^d   Tang, Huamei ^a   Peng, Zhihai ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

^c AFFILIATED HOSPITAL OF NINGXIA MEDICAL UNIVERSITY   (China)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Biomarker; FOXM1; Hepatocellular carcinoma; Orthotopic liver transplantation

Indexed keywords

FORKHEAD TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXM1; UNCLASSIFIED DRUG;

ACCURACY; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADULT; AGED; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM STAGING; PATIENT SELECTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME;

EID: 79955463277     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.03.009     Document Type: Article

References (27)

1. Schwartz M., Roayaie S., Konstadoulakis M. Strategies for the management of hepatocellular carcinoma. Nat. Clin. Pract. Oncol. 2007, 4:424-432.
2. Mazzaferro V., Regalia E., Doci R., Andreola S., Pulvirenti A., Bozzetti F., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. New Engl. J. Med. 1996, 334:693-699.
3. Bruix J., Llovet J.M. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002, 35:519-524.
4. Yao F.Y., Roberts J.P. Applying expanded criteria to liver transplantation for hepatocellular carcinoma: too much too soon, or is now the time?. Liver Transplant. 2004, 10:919-921.
5. Yao F.Y. Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am. J. Transplant. 2008, 8:1982-1989.
6. Guiteau J.J., Cotton R.T., Washburn W.K., Harper A., O'Mahony C.A., Sebastian A., et al. An early regional experience with expansion of Milan criteria for liver transplant recipients. Am. J. Transplant. 2010, 10:2092-2098.
7. Cillo U., Vitale A., Bassanello M., Boccagni P., Brolese A., Zanus G., et al. Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann. Surg. 2004, 239:150-159.
8. Cillo U., Vitale A., Grigoletto F., Gringeri E., D'Amico F., Valmasoni M., et al. Intention-to-treat analysis of liver transplantation in selected, aggressive treated HCC patients exceeding the Milan criteria. Am. J. Transplant. 2007, 7:972-981.
9. Sieghart W., Wang X., Schmid K., Pinter M., König F., Bodingbauer M., et al. Osteopontin expression predicts overall survival after liver transplantation for hepatocellular carcinoma in patients beyond the Milan criteria. J. Hepatol. 2011, 54:89-97.
10. Liu M., Dai B., Kang S.H., Ban K., Huang F.J., Lang F.F., et al. FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. Cancer Res. 2006, 66:3593-3602.
11. Chan D.W., Yu S.Y., Chiu P.M., Yao K.M., Liu V.W., Cheung A.N., et al. Over-expression of FOXM1 transcription factor is associated with cervical cancer progression and pathogenesis. J. Pathol. 2008, 215:245-252.
12. Li Q., Zhang N., Jia Z., Le X., Dai B., Wei D., et al. Critical role and regulation of transcription factor FoxM1 in human gastric cancer angiogenesis and progression. Cancer Res. 2009, 69:3501-3509.
13. Dai B., Kang S.H., Gong W., Liu M., Aldape K.D., Sawaya R., et al. Aberrant FoxM1B expression increases matrix metalloproteinase-2 transcription and enhances the invasion of glioma cells. Oncogene 2007, 26:6212-6219.
14. Calvisi D.F., Pinna F., Ladu S., Pellegrino R., Simile M.M., Frau M., et al. Forkhead box M1B is a determinant of rat susceptibility to hepatocarcinogenesis and sustains ERK activity in human HCC. Gut 2009, 58:679-687.
15. Wang Z., Ahmad A., Li Y., Banerjee S., Kong D., Sarkar F.H. Forkhead box M1 transcription factor: a novel target for cancer therapy. Cancer Treat. Rev. 2010, 36:151-156.
16. D'Angelica M., Fong Y. The liver. Sabiston Textbook of Surgery: The Biological Basis of Modern Surgical Practice 2008, 1463-1523. Saunders, Philadelphia. C.M. Townsend, R.D. Meauchamp, B.M. Evers, K.L. Mattox (Eds.).
17. Hamilton S.R., Aaltonen L.A. Pathology and genetics of tumors of the digestive system. World Health Organization Classification of Tumors 2000, 159-172. IARC Press, Lyon. P. Kleihues, L.H. Sobin (Eds.).
18. A.J.C.C., Liver, in: F.L. Greene, D.L. Page, I.D. Fleming (Eds.), AJCC Cancer Staging Manual, Springer-Verlag, New York, 2002, pp. 131-136.
19. Li D., Yan D., Tang H., Zhou C., Fan J., Li S., et al. IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis. Ann. Surg. Oncol. 2009, 16:3499-3506.
20. Sun H.C., Qiu Z.J., Liu J., Sun J., Jiang T., Huang K.J., et al. Expression of hypoxia-inducible factor-1 alpha and associated proteins in pancreatic ductal adenocarcinoma and their impact on prognosis. Int. J. Oncol. 2007, 30:1359-1367.
21. Yao F.Y., Ferrell L., Bass N.M., Watson J.J., Bacchetti P., Venook A., et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001, 33:1394-1403.
22. Broelsch C.E., Frilling A., Malago M. Should we expand the criteria for liver transplantation for hepatocellular carcinoma - yes, of course!. J. Hepatol. 2005, 43:569-573.
23. Mazzaferro V., Chun Y.S., Poon R.T., Schwartz M.E., Yao F.Y., Marsh J.W., et al. Liver transplantation for hepatocellular carcinoma. Ann. Surg. Oncol. 2008, 15:1001-1007.
24. Dai Z., Yu L., Zhou J., Qiu S.J., Fan J. Molecular markers and hepatocellular carcinoma: lending a helping hand in liver transplantation. Expert Rev. Gastroenterol. Hepatol. 2009, 3:211-213.
25. Mann C.D., Neal C.P., Garcea G., Manson M.M., Dennison A.R., Berry D.P. Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur. J. Cancer 2007, 43:979-992.
26. Carter S.L., Eklund A.C., Kohane I.S., Harris L.N., Szallasi Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat. Genet. 2006, 38:1043-1048.
27. Wu Q.F., Liu C., Tai M.H., Liu D., Lei L., Wang R.T., et al. induces cell cycle arrest and inhibits cell invasion in MHCC-97H cells in vitro. Acta Pharmacol. Sin. 2010, 31:361-366.